QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 protagenic-therapeutics-expects-to-file-its-quarterly-report-on-form-10-q-for-the-period-ended-june-30-2025-in-the-near-future-following-a-delay-attributable-to-the-completion-of-merger-related-consolidation-of-financial-statements-including-purchase-accounting-adjustments-pro-forma-financial-information-and-related-disclosures

NEW YORK, NY / ACCESS Newswire / August 22, 2025 / Protagenic Therapeutics, Inc. (NASDAQ:PTIX), a biopharmaceutical company dev...

 protagenic-therapeutics-ptix-shares-surge-on-clinical-trial-progress

Shares of Protagenic Therapeutics are trading sharply higher Thursday afternoon. The stock soared over 100% midday after the co...

 protagenic-completes-first-dose-injections-in-phase-i-multiple-dose-study-of-pt00114-topline-safety-data-expected-by-september-phase-2-launch-targeted-for-q1-2026

Dosing Completion Expected by End of August; Phase 2 Trial Expected to Begin in 1Q 2026NEW YORK, NY / ACCESS Newswire / August ...

 protagenic-therapeutics-announces-major-restructuring-transitions-to-virtual-operating-model-cuts-8m-in-annual-costs-halts-preclinical-programs-terminates-ceo-and-coo-changes-fiscal-year-end-and-refocuses-on-lead-clinical-trial-for-pt00114

Item 2.05 Costs Associated with Exit or Disposal Activities. On August 8, 2025, the Board of Directors (the "Board") of...

 protagenic-therapeutics-ptix-stock-soars-240-on-phytanix-merger

Protagenic Therapeutics shares soared 240% Monday on its all-stock merger with Phytanix Bio. New Phytanix targets CNS disorders...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION